Hepagene Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series B1

  • Latest Deal Amount
  • $40M

  • Investors
  • 4

Hepagene Therapeutics General Information

Description

Developer of liver disease pharmaceutical. The company is committed on research and development of drugs for non-alcoholic steatohepatitis (NASH), chronic Hepatitis B infection and liver cancer.

Contact Information

Website
www.hepagene.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 1, 5th Floor
  • 4560 Jin Ke Road, Pudong District
  • Shanghai, 201210
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Building 1, 5th Floor
  • 4560 Jin Ke Road, Pudong District
  • Shanghai, 201210
  • China
+86 021

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hepagene Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B1) 26-Apr-2021 $40M Completed Clinical Trials - Phase 2
2. Early Stage VC 15-May-2019 Completed Clinical Trials - Phase 1
1. Early Stage VC 01-Jan-2017 Completed Startup
To view Hepagene Therapeutics’s complete valuation and funding history, request access »

Hepagene Therapeutics Patents

  • 2

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Hepagene Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3070992-A1 Dimeric peptide inhibitors of apoptosis proteins Inactive 25-Jul-2017
EP-3606933-A1 Avermectin derivatives as fxr modulators Inactive 06-Apr-2017

Hepagene Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Loyal Valley Capital Growth/Expansion Minority
Oceanpine Capital Growth/Expansion Minority
Apricot Capital (Shanghai) Venture Capital Minority
Morningside Group Venture Capital Minority
To view Hepagene Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Hepagene Therapeutics FAQs

  • When was Hepagene Therapeutics founded?

    Hepagene Therapeutics was founded in 2016.

  • Where is Hepagene Therapeutics headquartered?

    Hepagene Therapeutics is headquartered in Shanghai, China.

  • What industry is Hepagene Therapeutics in?

    Hepagene Therapeutics’s primary industry is Drug Discovery.

  • Is Hepagene Therapeutics a private or public company?

    Hepagene Therapeutics is a Private company.

  • What is Hepagene Therapeutics’s current revenue?

    The current revenue for Hepagene Therapeutics is .

  • How much funding has Hepagene Therapeutics raised over time?

    Hepagene Therapeutics has raised $50M.

  • Who are Hepagene Therapeutics’s investors?

    Loyal Valley Capital, Oceanpine Capital, Apricot Capital (Shanghai), and Morningside Group have invested in Hepagene Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »